Shots:
Cugene to receive $48.5M up front & will be eligible to receive development, regulatory, commercialization, sales-based milestones, and additional fees upon licensing option along with royalties
AbbVie to acquire an exclusive option to license CUG252 & will lead the clinical development, manufacturing & commercialization activities for CUG252 if the option is exercised
Cugene’s CUG252 is an engineered IL-2 mutein that is used to treat autoimmune illnesses by selectively activating & expanding immune-suppressive Treg cells while lowering unwanted IL-2 activity on other IL-2 receptor-expressing cells. The therapy is being studied in a P-I study in healthy volunteers for the same indication
Ref: Abbvie | Image: Abbvie
